MedTrace Logo

Regional Analgesia Techniques for Laparoscopic Cholecystectomy

NCT07241949 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 147

Last updated 2026-05-13

No results posted yet for this study

Summary

This single-center, prospective, randomized controlled trial aims to compare the effects of paravertebral block (PVB), external oblique intercostal (EOI) block, and intravenous patient-controlled analgesia (PCA) with tramadol on postoperative pain and opioid consumption in patients undergoing elective laparoscopic cholecystectomy. The primary endpoint is total tramadol consumption within 24 hours postoperatively. Secondary outcomes include pain scores, additional analgesic use, incidence of nausea/vomiting, mobilization time, and length of hospital stay.

Conditions

  • Postoperative Pain
  • Laparoscopic Cholecystectomy
  • Paravertebral Block
  • External Oblique Intercostal Plane Block
  • Patient Controlled Analgesia

Interventions

PROCEDURE

Paravertebral Block (PVB)

Ultrasound-guided bilateral thoracic paravertebral block performed after induction of general anesthesia using 0.25% bupivacaine, 20 mL per side (total 40 mL).

PROCEDURE

External Oblique Intercostal Block (EOI Block)

Ultrasound-guided bilateral external oblique intercostal block performed after induction of general anesthesia with 0.25% bupivacaine, 20 mL per side (total 40 mL), injected between the external oblique and intercostal muscles.

DRUG

Tramadol IV Patient-Controlled Analgesia (PCA)

Intravenous patient-controlled analgesia (PCA) programmed to deliver tramadol with a maximum dose of 400 mg in 24 hours. Standard analgesia protocol includes IV paracetamol 1 g every 8 hours.

Sponsors & Collaborators

  • Cukurova University

    lead OTHER

Principal Investigators

  • Nurefsan Sadikoglu, MD · Cukurova University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-11-01
Completion
2026-12-05

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07241949 on ClinicalTrials.gov